BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Original) A pharmaceutical conjugate comprising a therapeutic component and an efficacy enhancing component, the efficacy enhancing component has the general formula A:



wherein X is



R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently an H, a C1-C10 hydrocarbon, or a linker.

2. (Original) A pharmaceutical conjugate of claim 1 wherein the therapeutic component and the efficacy enhancing component are directly joined by a covalent bond.

3. (Original) A pharmaceutical conjugate of claim 1 wherein the therapeutic component and the efficacy enhancing component are joined by a linker.

4. (Original) A pharmaceutical conjugate of claim 1 wherein R1 and R2 are Hs, and R3 is a linker.

5. (Original) A pharmaceutical conjugate of claim 1 wherein the efficacy enhancing component is a memantine.

6. (Original) A pharmaceutical conjugate of claim 1 wherein the linker is selected from the group consisting of:



Linker B



Linker C



Linker D



Linker E



Linker F



Linker G



Linker H

wherein R12 is an H or a C1-C10 hydrocarbon, m = 0 to 10, and n = 0 to 10.

7. (Original) A pharmaceutical conjugate of claim 1 wherein the therapeutic component is selected from the group consisting of NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, tyrosine kinase inhibitors and neuroprotectants.

8. (Original) A pharmaceutical conjugate of claim 1 wherein the therapeutic component is selected from the group consisting of quinoxaline, (2-imidozolin-2-ylamino) quinoxaline, 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, derivatives thereof and mixtures thereof.

9. (Currently amended) A pharmaceutical conjugate of claim 1 ~~comprising a therapeutic component and~~ wherein the efficacy enhancing component comprises a memantine, and the conjugate further comprises a linker ~~joins~~ joining the therapeutic component and the memantine.

10. (Currently amended) A pharmaceutical conjugate of claim 1 ~~comprising~~ wherein the therapeutic component comprises a timolol and the efficacy enhancing component comprises a memantine, and

the conjugate further comprises a linker ~~joins~~ joining the timolol and the memantine.

11. (Currently amended) A pharmaceutical conjugate of claim [[1]] 8 further comprising ~~a 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline and~~ a memantine, and a linker ~~joins~~ joining the ~~5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline~~ therapeutic component and the memantine.

12. (Original) A pharmaceutical conjugate of claim 1 wherein the therapeutic component and the efficacy enhancing component disassociate under physiological conditions.

13. (Currently amended) A pharmaceutical conjugate of claim 1 ~~being administered topically~~ provided in a composition suitable for topical administration to a patient.

14. (Currently amended) A pharmaceutical conjugate of claim 1 wherein the conjugate has an aqueous solubility, ~~the~~ a partition coefficient and/or ~~the~~ an affinity for melanin ~~is higher than~~ that is greater relative to a compound comprising the same therapeutic component which is not joined to an efficacy enhancing component.

15. (Original) A pharmaceutical conjugate of claim 1 being a salt.

16. (Original) A pharmaceutical conjugate comprising a therapeutic component and an efficacy enhancing component, the efficacy enhancing component has the general formula A:



wherein X is



R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently an H, a C1-C10 hydrocarbon, or a linker;

the linker is selected from the group consisting of:



Linker B



Linker C



Linker D



Linker E



Linker F



Linker G



Linker H

wherein R12 is an H or a C1-C10 hydrocarbon, m = 0 to 10, and n = 0 to 10.

17-23. (Cancelled)